Company / Cash & Equivalents
Inmune Bio, Inc. Cash & Equivalents History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$20.9M
FY2024
5-year range
$20.9M / $74.8M
FY2020-FY2024
Trend
-41.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $75M in FY2021 to $21M in FY2024.
Based on SEC 10-K filings.
$21M in FY2024 with a 3-year CAGR of -34.6%.
Declined from $52M to $21M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -34.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Inmune Bio, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -34.6%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 41.6% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $20.9M | -41.6% |
| FY2023 | $35.8M | -31.3% |
| FY2022 | $52.2M | -30.3% |
| FY2021 | $74.8M | +969.4% |
| FY2020 | $7.0M | +410.4% |
| FY2018 | $1.4M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026